Triptorelin
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Triptorelin: Hypertrichosis (disease)
One-Sentence Summary
Triptorelin is a gonadotropin-releasing hormone (GnRH) agonist marketed in Australia as an injectable. The TxGNN model predicts it may be relevant to hypertrichosis (disease), but there are no registered clinical trials and only 1 publication, a case report that does not show triptorelin treating the condition. Evidence is limited to the model prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Hypertrichosis (disease) |
| TxGNN Prediction Score | 1.0000 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Triptorelin belongs to the GnRH agonist class. These drugs suppress pituitary gonadotropin release and, with continued use, reduce gonadal sex hormone production.
In theory, lowering androgens could reduce androgen-dependent hair growth (hirsutism). However, hypertrichosis is generally androgen-independent, so the mechanistic link is weak. The high TxGNN score is not supported by clinical data. The only publication describes ciclosporin-induced hypertrichosis in a patient who was also taking triptorelin. That case suggests the hair growth occurred despite androgen suppression, which does not support a treatment role for triptorelin.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 41822646 | 2026 | Case report | Cureus | Generalised hypertrichosis developed after ciclosporin was started in a 25-year-old transgender woman with severe plaque psoriasis. She was also taking estradiol and triptorelin, so ciclosporin can cause hypertrichosis even during androgen suppression. Triptorelin was not studied as a treatment. |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 10907C | Decapeptyl | Injection 100 micrograms (as acetate) in 1 mL pre-filled syringe | Not stated in the data compiled for this report |
Safety Considerations
- Drug Interactions (100 interactions were found; examples below):
- Major: dolasetron
- Moderate: acarbose, metformin, pioglitazone, glimepiride, chlorpropamide, canagliflozin, dapagliflozin, empagliflozin, alogliptin, saxagliptin, albiglutide, dulaglutide, famotidine, clarithromycin, palonosetron, loperamide, bisacodyl, picosulfuric acid, polyethylene glycol (3350 with electrolytes)
Many of the moderate interactions involve glucose-lowering drugs, so glycaemic monitoring may be warranted. For warnings and contraindications, please refer to the TGA-approved Product Information (PI).
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone. No trial or publication studies triptorelin as a treatment for hypertrichosis, and the mechanism is weak because hypertrichosis is generally not androgen-driven.
To proceed, the following is needed:
- Mechanism of action data to assess the biological link
- Published clinical or preclinical studies that directly test triptorelin in hypertrichosis
- Warnings and contraindications from the TGA-approved Product Information (PI)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.